<code id='8E5C293569'></code><style id='8E5C293569'></style>
    • <acronym id='8E5C293569'></acronym>
      <center id='8E5C293569'><center id='8E5C293569'><tfoot id='8E5C293569'></tfoot></center><abbr id='8E5C293569'><dir id='8E5C293569'><tfoot id='8E5C293569'></tfoot><noframes id='8E5C293569'>

    • <optgroup id='8E5C293569'><strike id='8E5C293569'><sup id='8E5C293569'></sup></strike><code id='8E5C293569'></code></optgroup>
        1. <b id='8E5C293569'><label id='8E5C293569'><select id='8E5C293569'><dt id='8E5C293569'><span id='8E5C293569'></span></dt></select></label></b><u id='8E5C293569'></u>
          <i id='8E5C293569'><strike id='8E5C293569'><tt id='8E5C293569'><pre id='8E5C293569'></pre></tt></strike></i>

          knowledge

          knowledge

          author:knowledge    Page View:834
          Grail

          WASHINGTON — Grail is aggressively lobbying to get Medicare to pay for its cancer-screening test Galleri — but experts tell STAT that the company has a far more complicated path to that end than the makers of most medicines or medical devices.

          Grail’s controversial blood test Galleri screens for multiple cancers. The Food and Drug Administration has not yet approved it, so Medicare hasn’t had to make a decision on whether to cover it or not. Right now, most people pay for it out of pocket. It runs about $950.

          advertisement

          In general, Medicare covers FDA-approved medicines and medical devices that help diagnose or treat disease or injury. But there’s a catch for Grail: Medicare doesn’t cover tests that simply screen healthy people, as Galleri does.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          comprehensive

          The cancer drug shortage isn’t new — and neither are the solutions
          The cancer drug shortage isn’t new — and neither are the solutions

          PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

          read more
          At JPM 2024, hospital systems pitch financial strength to investors
          At JPM 2024, hospital systems pitch financial strength to investors

          AdobeSANFRANCISCO—HospitalleadersspentagoodchunkoftheirstagetimeattheJ.P.MorganHealthcareConferencet

          read more
          Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
          Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

          AdobeSometimes,anappleadayreallyisjustwhatthedoctorordered.Andforthepastseveralyears,organizationsli

          read more

          Paxlovid rebound happens. Why and to whom are still a mystery

          TheCovidantiviraldrugPaxlovidisdisplayedinNewYork.StephanieNano/APAsanemergencydepartmentphysicianin